DOCSLIB.ORG

Dr. J. ANGAYARKANNI , Phd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dr. J. ANGAYARKANNI , Phd Dr. J. ANGAYARKANNI , PhD. Date of Birth 19th February, 1970 Gender and Nationality Female; Indian Present Position Assistant Professor Department of Microbial Biotechnology, School of Biotechnology and Genetic Engineering, Bharathiar University Coimbatore – 641 046, Tamil Nadu, India Residential Address No. 5, 3rd Street East, Vellingri Nagar North, Navavoor Pirivu Bharathiar University Post Coimbatore – 641 046, Tamil Nadu, India Passport H0970002 (Valid up to 21.12.2018) E-mail ids [email protected] [email protected] Telephone Nos. 9003803022 (R); 09003790977 (H/P) ACADEMIC QUALIFICATIONS Degree Area of Institution Year of % of obtained specialization passing Marks Ph.D. Biotechnology Bharathiar University, India 2002 -- M.Sc. Environmental Bharathiar University, India 1996 69.33 Sciences B.Sc. Biochemistry Avinashilingam College for 1990 73.48 Women CV of Dr. J. Angayarkanni, PhD. 1/16 ACADEMIC EXPERIENCE (1990 – till date) In home country Institution Position / Rank Responsibilitie Duration s Bharathiar University, Assistant Professor, Teaching, 12.04.2009 to till India Department of Research and date Microbial Extension Biotechnology activities Bharathiar University, Lecturer, Department -do- 13.08.2008 to India of Microbial 11.04.2009 Biotechnology Bharathiar University, Lecturer, Department -do- 11.04.2005 to India of Biotechnology 13.08.2008 Bharathiar University, Technical Officer (SG) Lab in charge; 29.06.2000 to India Department of Handling Theory 10.04.2005 Biotechnology and practical Classes Bharathiar University, Technical officer, Lab-in-charge 29. 06.1990 to India Department of 28.06.2000 Biotechnology In overseas Institution Position/Rank Responsibilities Duration National University of BOYSCAST Research and 21.06.2010 to Singapore, Singapore Fellow, Extension activities 20.06.2011 Department of Biological Sciences ADMINISTRATIVE EXPERIENCE (1990 – till date) Type of duty Institution Duration Co-ordinator, PG Diploma in Bharathiar University 2007-2008 Microbial Biotechnology M.Sc. Program Co-ordinator Bharathiar University 2007-2009 Department of Microbial Biotechnology CV of Dr. J. Angayarkanni, PhD. 2/16 COURSES HANDLED Post-Graduate Course Institution Duration M.Sc. Bharathiar University 2005 to 2010 Biotechnology PG Diploma in Bharathiar University 2007 to2008 Microbial Biotechnology M.Sc. Industrial Bharathiar University 2005 to till date Biotechnology AWARDS BOYSCAST Fellowship award, Department of Science and Technology (DST), New Delhi, 21.06.2010 to 20.06.2011. RESEARCH EXPERIENCE (1994 – till date) SPECIALIZATION Cancer therapeutics MAJOR GOAL To formulate a combinatorial drug targeting cancer cell microbial metabolites inhibiting various targets such as Topoisomerase II, Telomerase, Angiotensin Converting Enzyme, Folate availability and MMP are under study. MINOR TARGETS Nm23 protein from Streptomyces sp. and GidA protein from Streptomyces sp. had been proven to posses anticancer property through Topoisomerase II inhibition Fatty acids from Streptomyces sp. had been proven to have Telomerase inhibition Antifolate enzyme Pterin deaminase enzyme from Micrococcus luteus, rat liver and rabbit liver is being purified for structural characterisation and sequence determination Hemeoxygenase enzyme from Candida tropicalis, Saccharomyces cerevisiae and Pseudomonas aerugenosa are being studied for their role in cancer Recombinant Bacterioferritin of Streptomyces coelicolor A3 had been proven to have Topoisomerase inhibition Lupeol from algae is being analysed for MMP inhibition Small peptides from bacteria and fungus are being analysed for their Angiotensin converting enzyme inhibiting property CV of Dr. J. Angayarkanni, PhD. 3/16 EXPECTED RESEARCH OUTCOME Determination of biological role of pterin deaminase in eukaryotes and prokaryotes after gene and protein sequence elucidation Formulation of combinatorial drug for cancer therapy targeting various pathways Research Guidance Program Ongoing Thesis Submitted Completed Ph. D. 08 03 11 M. Phil. 01 00 17 Ph.D. Guided – (12) S.No Name of the Title of the Dissertation Submission Viva date . Candidate date 1 Kavitha, V Interspecific protoplast fusion of June, 2010 July, 2011 Aspergillus terreus and A. flavus for the enhancement of Lovastatin production and its antihypercholesterolemic and anticancer applications 2 Sivasamy, R Anticancer potential of nucleoside December, 08.07. 11 diphosphate kinase from native isolate 2010 Streptomyces sp. By topoisomerase II inhibition 3 K. P. Renuka Devi Characterisation of Lipopolysaccharide February, 2012 27.05.13 from selected strains of Serratia marcescens and its biological activity 4 Infanta K. Teresa Enhancing the potency of GidA protein, a May, 2012 23.02.13 Antony novel topoisomerase II inhibitor for anticancer activity 5 S. D. Nisshanthini Evaluation of anticancer efficacy of 6- June, 2012 11.05.14 propionyl pterin characterized from cyanide utilizing bacterium Bacillus subtilis 6 U. Priyadharshini Sequence analysis and biological June, 2012 08.08.13 implications of pterin deaminase from native isolate Micrococcus luteus B1252 7 R.K. Sumathi Characterization and applications of Heme December, 23.12.14 oxygenase from Native isolate Candia 2012 tropicalis 8 N.Vijayarani Anticancer effect of antifolate enzyme pterin October, 2013 20.11.14 deaminase from native isolate Aspergillus terreus JQ 436691 9 M. Mahalakshmi Bioconversion of cellulosic agrowastes for March, 2014 17.11.14 ethanol production 10 M. Dhanalakshmi Biological characterization and anticancer April, 2014 potential of active compound from fresh CV of Dr. J. Angayarkanni, PhD. 4/16 water algae Chlorosarcinopsis sp. 11 P. Kiruthika Biologically active pigment from marine 18th December, actinomycete for anticancer activity 2014 12 Lida Ebrahimi Imminent Angiotensin converting enzyme 23rd December, inhibitor from microbial source for 2014 17.07.15 anticancer therapy 13 K. Ayub Nawaz Identification and characterization of 29th June, 2015 13.01.16 angiotensin coverting enzyme inhibitory peptide from Cajanus cajun by Aspergillus niger – An anticancer approach 14 Satheesh kumar Prospective inhibitors of Angiotensin 09th October, Converting enzyme from Marine bacterium 2015 Lactobacillus plantarum M.Phil. Guided – (17) S.No. Name of the Title of the Dissertation Month / Candidate Year 1 Prasanna, R Novel Angiotensin converting enzyme 2007 inhibitor from Aspergillus sp. by solid state fermentation 2 Kiran, K.G. Isolation of telomerase inhibitor from 2008 native isolate Streptomyces sp. 3 Jancy Magdalene Topoisomerase II inhibitor from 2009 Streptomyces species 4 Frieda Nancy Purification and characterization of 2009 HO-1 from Candida albicans 5 Asher Rajkumar, R Identification of MMP inhibitor from March Marine brown algae 2010 6 Maheskumar, A Isolation and characterization of July 2010 pterin from native isolate Staphylococcus sp. 7 T. Shanthi Biological activity of pigment from a Sep. 2010 soil microbe 8 Parthiban, S Production and optimization of pterin Sep. 2010 deaminase from soil fungi 9 Sabarathinam, S Biological and structural Sep. 2010 characterization of ptern deaminase from rat liver 10 Mehala, S Anti-fungal metabolites production by Sep.2011 actinomycetes induced in co-culture system against Aspergillus niger 11 Saraswathi, A. Biochemical characterization of pterin Oct. 2012 deaminase from native isolate Microbacterium sp. CV of Dr. J. Angayarkanni, PhD. 5/16 12 M.Thandeeswaran Isolation and purification of pterin April 2013 deaminase from Rabbit liver 13 J. Kishore kumar Isolation of Matrix metalloproteinases April 2013 (MMP-2 and MMP-9) from Rat liver. 14 S. Vanishiri Characterization of Hemeoxygenase April from Saccharomyces cerevisiae 2013 15 R. Mahendran Purification of Pterin deaminase from March native soil bacterium 2014 16 K. Vidhya Inhibition of heme oxygenase by 2015 novel imidazole derivatives – A strategy for cancer treatment 17 M. Karuppusamy Molecular architechture of pterin 2015 deaminase from Saccharomyces sp. FUNDED RESEARCH PROJECTS Research Project grants (04) Project title Duration Amount Funding Status (Rs) agency Novel 2010- 29,50,000 Department On going derivative of 2013 of Science and F. No. SR/SO/HS-131/2008 Lovastatin as Technology dated 25.11.2010 anticancer (DST), New agent Delhi Semisynthetic 2008- 14,42,943 Indian 5/13/03/2007-NCD-III; Dt. complexes of 2011 Council for 07.10.2008 ruthenium for Medical Completed antitumour Research property of (ICMR), New Topoisomerase Delhi inhibitors Isolation of 2007- 15,20,000 Department BT/PR10273/GBD/27/86/2007 telomerase 2010 of Dt. 18.12.2007 inhibitor from Biotechnology Completed soil microbe (DBT), New Delhi Purification and 2007- 7,87,600 University F.No.32-541/2006 (SR) Dt. characterization 2010 Grants 25.04.2007 of pterin Commission Completed deaminase from (UGC), New microbial Delhi source CV of Dr. J. Angayarkanni, PhD. 6/16 PATENTS 1. Mammalian Pterin deaminase with antioxidant activity (2259/CHE/2009. dt. 18.09.2009), India. (filed) 2. Bacterial pterin deaminase with antitumor property (2260/CHE/2009. dt. 18.09.2009), India. (filed) Sequence submitted (34) 1. Ayub Nawaz,K.A., Angayarkanni,J., Kiran,K.G., Thandeeswaran,M. and Palaniswamy,M. Aspergillus niger strain CTL6 internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence GenBank accession : KR535626.1 (2015) 2. Mahendran,R., Kiran,K., Ayub Nawaz,K., Subhash Chandra Bose,V. and Angayarkanni,J.Micrococcus
Load more

Recommended publications
  • TETRAHYDROBIOPTERIN DEFICIENCY and BRAIN NITRIC OXIDE METABOLISM by Michael Peter Brand
    TETRAHYDROBIOPTERIN DEFICIENCY AND BRAIN NITRIC OXIDE METABOLISM By Michael Peter Brand A thesis submitted as partial fulfilment for the degree of Doctor of Philosophy in the Faculty of Science at the University of London. March 1997 Institute of Neurology Department of Neurochemistry Queen Square London WCIN 3BG ProQuest Number: 10055824 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10055824 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract. Tetrahydrobiopterin is an essential cofactor for the aromatic amino acid mono­ oxygenase group of enzymes. Inborn errors of tetrahydrobiopterin metabolism result in hyperphenylalaninaemia and impaired catecholamine and serotonin turnover. Tetrahydrobiopterin is also a cofactor for all known isoforms of nitric oxide synthase (NOS). The effect of tetrahydrobiopterin deficiency on brain nitric oxide metabolism has to date been given little consideration. In this thesis the effect of tetrahydrobiopterin deficiency on brain nitric oxide metabolism has been studied using a mouse model of tetrahydrobiopterin deficiency, the hph-1 mouse. Tetrahydrobiopterin was measured in 10 and 30 day old mice in whole brain and cerebellum.
    [Show full text]
  • Advances in Biotechnology July 10-12, 2017 Dubai, UAE
    Yu-Chen Hu, Adv Biochem Biotehcnol 2017, 02: 05 (Suppl) http://dx.doi.org/10.29011/2574-7258.C1-003 International Conference on Advances in Biotechnology July 10-12, 2017 Dubai, UAE Baculovirus-mediated MIR-214 suppression shifts osteoporotic ASCS differentiation towards osteogenesis and improves osteoporotic bone defects repair Yu-Chen Hu*, Kuei-Chang Li, Mu-Nung Hsu and Mei-Wei Lin National Tsing Hua University, Hsinchu, Taiwan Osteoporotic patients often suffer from bone fracture but its healing is compromised due to impaired osteogenesis potential of bone marrow-derived mesenchymal stem cells (BMSCs). Here we aimed to exploit adipose-derived stem cells from ovariectomized (OVX) rats (OVX-ASCs) for bone healing. We unraveled that OVX-ASCs highly expressed miR-214 and identified 2 miR-214 targets: CTNNB1 (b-catenin) and TAB2. We demonstrated that miR-214 targeting of these two genes blocked the Wnt pathway, led to preferable adipogenesis and attenuated osteogenesis, undermined the osteogenesis of co- cultured OVX-BMSCs, enhanced exosomal miR-214 release and altered cytokine secretion. As a result, OVX-ASCs implantation into OVX rats failed to heal critical-size metaphyseal bone defects. However, using hybrid baculoviruses expressing miR-214 sponges to transduce OVX-ASCs, we successfully suppressed miR-214 levels, activated the Wnt pathway, upregulated osteogenic factors -catenin/Runx2, downregulated adipogenic factors PPAR-g and C/EBP-a, shifted the differentiation propensity towards osteogenic lineage, enhanced the osteogenesis of co-cultured OVX-BMSCs, elevated BMP7/osteoprotegerin secretion and hindered exosomal miR-214/osteopontin release. Consequently, implanting the miR-214 sponge-expressing OVX-ASCs tremendously improved bone healing in OVX rats.
    [Show full text]
  • L–Asparaginase
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 8, Issue 3, 2016 Original Article SCREENING AND PRODUCTION OF ANTICARCINOGENIC ENZYME FROM ESCHERICHIA COLI CTLS20: L–ASPARAGINASE MURUGESAN THANDEESWARANa, RAMASAMY MAHENDRANa, KALARIKKAL GOPIKRISHNAN KIRANa, K. A. AYUB NAWAZa, MUTHUSAMY PALANISWAMYb, ANGAYARKANNI JAYARAMANa* aCancer Therapeutics Lab, Department of Microbial Biotechnology, Bharathiar University, Coimbatore 641046, bDepartment of Microbiology, Karpagam University, Coimbatore 641021 Email: [email protected] Received: 13 Dec 2015 Revised and Accepted: 25 Jan 2016 ABSTRACT Objective: The objective of this study was attempted to screen the production of L-asparaginase from bacteria isolated from soil samples and its enzymatic activity. Methods: Screening of L-asparaginase was performed using phenol red indicator growth medium from which the positive strains were chosen based on the colour change. The enzyme production of L-asparaginase was established by submerged fermentation followed by the molecular detection of the efficient bacterial strains. Results: The enzyme production was undertaken by submerged fermentation with the evaluation of enzymatic activity and protein content. This revealed that the strain Escherichia coli CTLS20 produced a higher yield of L-asparaginase (30.22 IU/mg), 16.91 µg/ml of protein with the specific activity of 1.787 IU/mg when compared with other bacterial strains. The efficient bacterial strains were also confirmed by 16S rRNA sequence as Escherichia coli, Acinetobacter baumnnii, Klebsiella pneumoniae and the phylogenetic tree construction revealed the evolutionary relationship of the bacterial strains. Conclusion: This study indicated that the bacterial strain E. coli CTLS20 had the ability for the higher production of L-asparaginase. This novel higher yielding bacterial asparaginase is highly desirable as better alternatives in cancer therapy.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • Goble Biochemistry 2
    Subscriber access provided by - Access paid by the | UCSF Library Article Deamination of 6-Aminodeoxyfutalosine in Menaquinone Biosynthesis by Distantly Related Enzymes Alissa Marie Goble, Rafael Toro, Xu Li, Argentina Ornelas, Hao Fan, Subramaniam Eswaramoorthy, Yury V. Patskovsky, Brandan Hillerich, Ronald D. Seidel, Andrej Sali, Brian K. Shoichet, Steven C. Almo, Subramanyam Swaminathan, Martin E. Tanner, and Frank Michael Raushel Biochemistry, Just Accepted Manuscript • DOI: 10.1021/bi400750a • Publication Date (Web): 23 Aug 2013 Downloaded from http://pubs.acs.org on August 28, 2013 Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,945,049 Hamaya Et Al
    United States Patent (19) 11 Patent Number: 4,945,049 Hamaya et al. (45) Date of Patent: Jul. 31, 1990 (54) METHOD FOR PREPARING MAGNETIC 0187.192 11/1983 Japan ................................... 435/168 POWDER 60-172288 9/1985 Japan. 2055092 3/1987 Japan ................................... 435/168 75) Inventors: Toru Hamaya, 1-D, Daiichiseifuso, 62-171688 7/1987 Japan. 5-5, Minami 1-chome, Meguro-ku, 62-294089 12/1987 Japan. Tokyo 152; Koki Horikoshi, 39-8, 2192870 4/1988 United Kingdom ................ 435/168 Sakuradai 4-chome, Nerima-ku, Primary Examiner-Herbert J. Lilling Tokyo 176, both of Japan Attorney, Agent, or Firm-Oblon, Spivak, McClelland, 73 Assignees: Research Development Corporation; Maier & Neustadt Toru Hamaya; Koki Horikoshi, all of Tokyo, Japan; a part interest 57 ABSTRACT The present invention relates to a method for preparing 21 Appl. No.: 343,263 magnetic powder comprising homogeneous and fine 22 PCT Filed: Aug. 18, 1988 particles using an alkali-producing enzyme. The object of the present invention is to provide a method suitable (86 PCT No.: PCT/JP88/00814 for preparing magnetic powder comprising relatively S371 Date: Apr. 14, 1989 small particles, for instance, fine particles having a par ticle size ranging from 50 to 500 nm. The present inven S 102(e) Date: Apr. 14, 1989 tion relates to a method for preparing at least one mem (87. PCT Pub. No.: WO89/01521 ber selected from the group consisting of iron oxides, iron hydroxides and iron oxyhydroxides which com PCT Pub. Date: Feb. 23, 1989 prises the step of alkalizing a solution containing iron 30 Foreign Application Priority Data ions utilizing an alkali-producing enzyme and a sub Aug.
    [Show full text]
  • 15. Leveraging Structure for Enzyme Function Prediction: Methods
    Review Leveraging structure for enzyme function prediction: methods, opportunities, and challenges 1,2 1,2 Matthew P. Jacobson , Chakrapani Kalyanaraman , 1,2 1,2 Suwen Zhao , and Boxue Tian 1 Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, CA 94158, USA 2 California Institute for Quantitative Biomedical Research, University of California, San Francisco, CA 94158, USA The rapid growth of the number of protein sequences One fundamental challenge is that there is no univer- that can be inferred from sequenced genomes presents sal criterion sufficient to determine when a pair of pro- challenges for function assignment, because only a teins are likely to have the same or different functions; small fraction (currently <1%) has been experimentally even if two proteins are highly homologous to one another characterized. Bioinformatics tools are commonly used and have similar structures, a change of only a few to predict functions of uncharacterized proteins. Recent- residues in the active site can change the functional ly, there has been significant progress in using protein specificity [5]. A second fundamental challenge is that structures as an additional source of information to infer annotation transfer, by definition, cannot identify new, aspects of enzyme function, which is the focus of this uncharacterized protein functions. These challenges review. Successful application of these approaches has have motivated the development of diverse approaches led to the identification of novel metabolites, enzyme to protein functional characterization and prediction. activities, and biochemical pathways. We discuss oppor- Such approaches use additional types of information tunities to elucidate systematically protein domains of beyond protein sequence, such as high-throughput meta- unknown function, orphan enzyme activities, dead-end bolomics [6], RNA profiling [7–9], proteomics [10,11], and metabolites, and pathways in secondary metabolism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • Isolation and Screening of Pterin Deaminase Producing Fungi From
    International Journal of Applied Research 2016; 2(6): 342-344 ISSN Print: 2394-7500 ISSN Online: 2394-5869 Isolation and screening of pterin deaminase producing Impact Factor: 5.2 IJAR 2016; 2(6): 342-344 fungi from soil samples www.allresearchjournal.com Received: 16-04-2016 Accepted: 17-05-2016 Vijayarani Nallathambi, Angayarkanni Jayaraman and Nallathambi Vijayarani Nallathambi Govindasamy Department of Microbial, Biotechnology, Bharathiar Abstract University, Coimbatore, Tamil Pterin deaminase is a folate deaminating enzyme has been reported to have antitumour activity against Nadu, India. leukemic cell line and melanoma induced in mice. In the present study, a total of twenty five fungal Angayarkanni Jayaraman cultures were isolated from soil sample collected in and around the city of Coimbatore district. The Department of Microbial, diversity of fungal isolates was found to be higher in the cultivated land soil compared to unattended Biotechnology, Bharathiar barren land and coconut plantation soils. A rapid plate assay method was used for the first time to University, Coimbatore, Tamil screen the pterin deaminase producing fungus using folate as a substrate in modified czapek Dox agar Nadu, India. medium. The strain CLS-6 was selected based on the zone of clearance and pink colouration around the zone with a maximum enzyme activity of 40.2 IU/ml and 36.5 mg/ml of protein for further purification Nallathambi Govindasamy and characterization. Department of Millets, Tamil Nadu Agricultural University, Keywords: Pterin deaminase, Lumazine, Folate, Substrate, Cancer Coimbatore, Tamil Nadu, India 1. Introduction Fighting cancer is considered as one of the most important areas of research in medicine and immunology.
    [Show full text]